Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Discussioni nella community
- (✅) GSK Abspaltung Haleon GB00BMX86B70 nicht unterstützt
Sven III in Schnack6 16
Notizie Vai al feed delle notizie
GSK shares fall after weaker vaccine sales, restructuring charges and profit decline
GSK reported a 19% drop in pre-tax profit to £1.9bn for July–September and Q3 revenue up 5% to £8.9bn, driven by specialty medicines while vaccine sales fell 2% (Shingrix -5%, Arexvy -24%). The company booked £318m of restructuring charges this quarter with total restructuring costs expected at £2.4bn and says more charges will follow as it pursues a three-year cost reduction plan. Investors were also concerned by the looming patent expiry for HIV drug dolutegravir even as GSK reiterates guidance, plans increased R&D, and targets over £40bn annual revenue by 2031. » Altro su theguardian.com
GSK: investment three years ago would have yielded a 15.15 percent gain
Three years ago GSK shares closed at £15.20; with the closing price on 09.10.2026 of £17.50, an investment of £100 would be worth £115.15 today (+15.15 percent). The calculation does not take stock splits or dividends into account. GSK most recently reached a market capitalization of £74.90 billion. » Altro su finanzen.net
GSK: £1,000 investment from 2016 to 2026 would have incurred a 10.5% loss
If GSK shares had been bought for £1,000 on 28.09.2016 (price £20.69), the holding would now be 48.338 shares. At a closing price of £18.51 on 25.09.2026 the investment would be worth £894.74, a loss of 10.53%. The calculation does not take account of stock splits or dividends; market capitalization most recently £74.05 billion. » Altro su finanzen.net
GSK: a £100 investment five years ago would have grown by 5.94 percent
Five years ago the closing price of GSK stock was £17.72; on 18 September 2026 the stock stood at £18.78. A £100 investment would have bought 5.643 shares then and would be worth £105.94 today, an increase of 5.94 percent. The calculation excludes stock splits and dividend payments; market capitalization most recently stood at £75.23 billion. » Altro su finanzen.net
GSK buys TCE cancer therapy from Chimagen for up to $750 million
GSK acquires a trispecific T‑cell engager (TCE) therapy from Chimagen and makes an upfront payment for worldwide rights; the deal could reach up to $750 million. The therapy targets treatment of multiple myeloma and is intended to improve tolerability and efficacy by binding to T cells and two tumor‑associated antigens. GSK plans to advance the program into phase‑1 studies in 2027; Chimagen will also receive additional development and commercialization milestone payments tied to success. » Altro su finanzen.net
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | marzo 2026 | YoY |
|---|---|---|
| Ricavi | 7,62 Mld | - |
| Utile lordo | 5,75 Mld | - |
| Utile netto | 1,73 Mld | - |
| EBITDA | 2,61 Mld | - |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 0 € |
| Dividendi | No |
Beta | 0,25 |
Rapporto P/E | 17,50 |
Rapporto PEG | -0,85 |
Rapporto P/B | 4,04 |
Rapporto P/S | 2,26 |
Profilo aziendale
GSK plc, insieme alle sue controllate, si occupa della creazione, scoperta, sviluppo, produzione e commercializzazione di prodotti farmaceutici, vaccini, farmaci da banco e prodotti per la salute destinati ai consumatori nel Regno Unito, negli Stati Uniti e a livello internazionale. L'attività si articola in quattro segmenti: Pharmaceuticals, Pharmaceuticals R&D, Vaccines e Consumer Healthcare. L'azienda offre prodotti farmaceutici costituiti da medicinali nelle aree terapeutiche quali malattie respiratorie, HIV, immuno-infiammazione, oncologia, antivirali, sistema nervoso centrale, cardiovascolare e urogenitale, metabolismo, antibatterici e dermatologia. Fornisce inoltre prodotti per la salute destinati ai consumatori nelle categorie benessere, salute orale, nutrizione e salute della pelle. L'azienda propone i propri prodotti per la salute destinati ai consumatori sotto forma di spray nasali, compresse, sciroppi, pastiglie, gomme e cerotti transdermici, caplets, gocce di sciroppo per neonati, sospensioni liquide, salviettine, gel, compresse effervescenti, dentifrici, spazzolini da denti, collutori, adesivi e detergenti per protesi dentarie, creme topiche e cerotti non medicati, balsamo per le labbra, gommose e caramelle morbide. Ha accordi di collaborazione con 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; e CureVac AG., nonché una partnership strategica con IDEAYA Biosciences, Inc. e Vir Biotechnology, Inc. In precedenza la società era nota come GlaxoSmithKline plc e ha cambiato denominazione in GSK plc nel maggio 2022. GSK plc è stata fondata nel 1715 ed ha sede a Brentford, nel Regno Unito.
| Nome | GlaxoSmithKline |
| CEO | Emma N. Walmsley |
| Sede centrale | Brentford,
Regno Unito |
| Sito web | |
| Settore | Sanità |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 22/05/1972 |
| Dipendenti | 90.096 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
London Stock Exchange | GSK.L |
XETRA | GS7.DE |
Frankfurt | GS71.F |
SIX | GSK.SW |
